顺铂联合多西他赛或吉西他滨治疗晚期非小细胞肺癌的临床对照研究

目的：比较多西他赛联合顺铂与吉西他滨联合顺铂治疗晚期非小细胞肺癌（NSCLC）的近期临床疗效和不良反应。方法：将84例晚期非小细胞肺癌患者随机分为多西他赛和顺铂组（DC组）42例及吉西他滨和顺铂组（GC组）42例。同一方案治疗2个周期评估近期疗效及不良反应。结果：评价入组的84例患者的近期疗效,DC组和GC组有效率分别为45.2%和40.5%,两组之间有效率差异无统计学意义（P〉0.05）。毒副反应主要为骨髓抑制和消化道反应。结论：多西他赛加顺铂与吉西他滨加顺铂方案治疗晚期非小细胞肺癌均具有较好的临床疗效且两者的疗效相似,不良反应可以耐受,可以用于临床一线治疗。

A study of cisplatin plus docetaxel or gemcitabine in treating advanced nonsmall cell lung cancer

Objective： To compare the efficacy and adverse reactions between DC and GC regimens in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods： 84 cases with advanced NSCLC were randomized devided into two groups, 42 cases received the DC regimen chemotherapy and 42 cases received the GC regimen chemotherapy.The efficacy and adverse reactions were evaluated after two cycle. Results： The effective rate of the DC group and the GC group was 45.2% and 40.5%. There was no statistically significant difference between the two groups （P〉0.05）. The major toxicities were bone marrow suppression and gastrointestinal reaction. Conclusion： The DC and GC regimens in the treatment of advanced NSCLC has good clinical efficacy. Both the curative effect are the same. The toxicities are tolerable and it can be used as clinical treatment.